cerca CERCA
Lunedì 18 Ottobre 2021
Aggiornato: 02:04
Temi caldi

Salute_E_Benessere Salute_E_Benessere Chimica_E_Farmacia Chimica_E_Farmacia Chimica_E_Farmacia

comunicato stampa

MedAlliance announces completion of enrollment in Japanese SELUTION SLR™ Study

GENEVA, Sept. 23, 2021 /PRNewswire/ -- MedAlliance, with its Japanese partner MDK Medical, has completed enrollment in the clinical study of its novel Sirolimus Drug Eluting Balloon (DEB), SELUTION SLR™, for the treatment of peripheral arterial disease (PAD). This follows the acceptance of a Clinical Trial Notification (CTN) by Japan's Pharmaceutical and Medical Device Agency (PMDA) in June 2020.

European Hematology Association: Humoral Response to the Pfizer/BioNTech BNT162b2 Vaccine Is Impaired in Patients Receiving CAR-T or High-Intensity Immunosuppressive Therapy

THE HAGUE, Netherlands, June 12, 2021 /PRNewswire/ -- The Pfizer/BioNTech BNT162b2 vaccine has been approved for the prevention of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and is recommended for immunosuppressed patients. However, its efficacy and safety in patients undergoing immunologic cell therapy have not been well-documented. In this study, we evaluated the efficacy and safety of the BNT162b2 vaccine in patients that underwent hematopoietic cell transplantation...

European Hematology Association- First-Line Ibrutinib + Venetoclax Is Superior to Chlorambucil + Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocyte Lymphoma

THE HAGUE, Netherlands, June 12, 2021 /PRNewswire/ - The combination of ibrutinib and venetoclax may be effective for treating patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) due to the complementary mechanisms of action of the two targeted therapies. Ibrutinib mobilizes CLL cells from the lymph nodes and inhibits cancer cell proliferation while venetoclax kills any circulating cancer cells. The GLOW study is the first randomized clinical trial to investigate the e...

ora in
Prima pagina
articoli
in Evidenza